An AMH result usually arrives as a single figure with nothing attached to it. That is the real problem, not the test. The number only becomes useful once you know two things: how it compares with other women your age, and what the marker is measuring in the first place. Here is what the research shows, where the misreadings tend to happen, and what you can reasonably do with your result.
Key takeaways
- An AMH result only means something next to an age matched reference. A low figure at 35 can be completely ordinary, and a high one is not automatically good news.
- AMH estimates how many follicles you have left, not how good they are. A low result does not mean you cannot conceive naturally.
- High AMH can point towards PCOS rather than towards strong fertility. The two situations are biologically different and are routinely confused.
- Some supplements do have clinical evidence behind them for ovarian function, though when you take them matters more than most people expect.
- Retesting on the same platform over time tells you far more than any single reading ever will.
What AMH is counting
AMH stands for Anti-Müllerian hormone. It is produced by the granulosa cells of the small developing follicles in your ovaries, so the level in your blood works as a rough proxy for how many follicles you still have in reserve. That is the whole of what it measures. It says nothing directly about the quality of those eggs, about when you will reach menopause, or about your chances of getting pregnant. Those are separate questions.
Most of the unnecessary anxiety that follows a result comes from treating follicle quantity as though it were egg quality. The two are related, but AMH only speaks to one of them.
There is one practical advantage worth knowing. Unlike LH, FSH or estradiol, AMH does not shift much across the menstrual cycle, so you can test on any day of the month. That is part of why it suits a pharmacy or point of care format.
What it cannot tell you: your individual chance of conceiving naturally, your egg quality, or a precise timeline to menopause. Those require a fuller clinical picture.
The number that changes the reading: your age
A result of 1.4 ng/mL means something very different at 28 than it does at 38. At 35 it sits on the median, which is to say it is exactly what would be expected at that age.
A 2025 study published in Frontiers in Endocrinology analysed 22,920 AMH results and found the median falling from 3.3 ng/mL at age 25 to 0.5 ng/mL at age 40. That decline is normal biology, not a problem to be solved.
Age Median AMH Women with low reserve (<1.2 ng/mL) 25 3.3 ng/mL ~16% 30 2.5 ng/mL ~24% 35 1.4 ng/mL ~50% 40 0.5 ng/mL ~73% 45 Near undetectable ~96%
Source: Aslan et al., Frontiers in Endocrinology, 2025 (n=22,920)
The spread within each age band is wide as well. At 35 the 25th percentile is 0.5 ng/mL and the 75th is 2.9 ng/mL, and both are normal for that age. Without an age matched reference point, the figure on its own tells you very little.
The clinical threshold used to flag diminished ovarian reserve (DOR) is an AMH below 1.2 ng/mL. It is a useful working benchmark for specialists, but it needs the same context as everything else here. Close to half of all 35 year olds fall below it. By 40, around 73% do. Many of those women conceive naturally.
High AMH is not always good news
A high result needs interpreting just as carefully as a low one, and for the same reason.
Women with polycystic ovary syndrome (PCOS) typically have two to three times more antral follicles than average. Because AMH comes from those follicles, their readings are correspondingly elevated, often above 4 to 5 ng/mL and sometimes a good deal higher. This is not a fertility advantage. It is a sign that the follicles are not cycling normally.
In 2023, updated international PCOS guidelines formally accepted AMH as an alternative to ultrasound follicle counts as a diagnostic criterion, but only in adults, and only when at least one other criterion is also present, such as irregular cycles or signs of elevated androgens. A high AMH on its own does not diagnose PCOS. It raises a flag worth following up.
Age stratified PCOS signal thresholds (Wang et al., 2025)
Age band AMH threshold 20 to 24 ≥7.46 ng/mL 25 to 29 ≥4.55 ng/mL 30 to 34 ≥4.19 ng/mL 35 to 39 ≥3.57 ng/mL
These values come from a single centre Chinese population study validated against the 2003 Rotterdam criteria. The authors note that multicentre validation is needed before clinical implementation, so treat the figures as indicative rather than definitive. Absolute thresholds will also vary by assay platform.
In practice: if your AMH is high and your cycles are irregular, that combination deserves proper investigation rather than reassurance about your reserve.
What the evidence says about supporting ovarian reserve
Some supplements do have genuine clinical backing for ovarian function, and the research is fairly specific about what they do and when they need to be taken.
Vitamin D. A targeted intervention study gave women with low AMH and vitamin D deficiency 50,000 IU per week for three months. Median AMH rose from 0.50 to 0.79 ng/mL, a statistically significant increase. BMC Endocrine Disorders, 2021
CoQ10. A randomised controlled trial in 80 women with low ovarian reserve found that 200 mg per day for eight weeks before IVF nearly doubled clinical pregnancy rates (35% versus 17.5%) and significantly increased the number of mature oocytes retrieved. JPTCP, 2024
On vitamin D, the researchers themselves note that the rise in AMH may reflect changes in AMH gene expression rather than an actual increase in follicle count. The finding is promising but not yet settled, and further trials are needed to confirm it.
On CoQ10, the evidence is stronger and better replicated. A 2024 meta-analysis across six randomised controlled trials involving 1,529 women corroborated improvements in ovarian stimulation outcomes. An earlier trial in 169 women (Xu et al., 2018) found that the CoQ10 group retrieved a median of 4.19 oocytes against 3.32 in the control group, again a statistically significant difference.
There is a timing point that often gets missed. Follicles take roughly 90 days to mature from early stage through to ovulation, so both vitamin D and CoQ10 need to be present well before any conception attempt or IVF cycle if they are going to influence the follicles that will actually be recruited. Starting a week beforehand does not do anything, because the biology runs on a longer clock.
These findings apply to supplementation in women with identified deficiency or diminished reserve, in clinical settings. Supplementation is not a substitute for medical advice, and neither vitamin D nor CoQ10 is a fertility treatment.
Why your result looks different depending on where you test
AMH assays are not standardised across labs and testing platforms. A reading of 2.1 ng/mL from one kit is not the same as 2.1 ng/mL from another, because they use different calibration methods and different reference populations.
That has a direct practical consequence: comparing your result against a population table built on a different assay will give you a misleading read. What matters more than any single absolute figure is your own trend over time on the same platform.
A single data point cannot tell you much. A series of results from the same test, tracked across 12 to 18 months, gives you something you can act on. You are not aiming at a target number so much as watching a direction.
The bottom line
- Always read your AMH result against an age matched reference. A number without age context tells you almost nothing.
- If your AMH is high and your cycles are irregular, treat that as a signal worth investigating rather than as reassurance.
- A low AMH result is not an infertility diagnosis. It reflects reserve size, not egg quality, and it does not predict your ability to conceive naturally.
- If you are considering vitamin D or CoQ10 for ovarian support, start at least 90 days before you need them to work. The follicles that matter are already developing.
- Retest on the same platform over time. One result is a snapshot, and a series is what you can plan around.
Welleo's AMH test is designed to be taken at your pharmacy, on any day of your cycle, with a personalised supplement protocol generated from your result in the app. If your number raised more questions than it answered, that is what it is for.
Find your nearest Welleo pharmacy partner
References
- Aslan K, et al. Age-specific anti-Müllerian hormone nomogram and diminished ovarian reserve prevalence across reproductive ages: a cross-sectional study of 22,920 women. Frontiers in Endocrinology. 2025.
- Teede HJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility. 2023;120:767-93.
- Irani M, et al. Effect of vitamin D supplementation on anti-Müllerian hormone levels in women with diminished ovarian reserve and vitamin D deficiency: a randomised controlled trial. BMC Endocrine Disorders. 2021.
- Alahmar AT, et al. Coenzyme Q10 supplementation in women with poor ovarian response undergoing IVF: a randomised controlled trial. Journal of Pharmacy and Technology in Clinical Practice (JPTCP). 2024. n=80.
- Lin J, et al. Coenzyme Q10 supplementation and IVF/ICSI outcomes in women with diminished ovarian reserve: a systematic review and meta-analysis of 6 RCTs (n=1,529). Annals of Medicine. 2024.
- Xu Y, et al. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomised controlled trial. Reproductive Biology and Endocrinology. 2018. n=169.
- Wang Z, Teng X, Liu Y, Shen Y, Ma L, Chen Y. Establishment of age-related AMH screening cutoffs in Chinese women with PCOS: a retrospective study using propensity score matching analysis. BMC Endocrine Disorders. 2025;25:153. DOI: 10.1186/s12902-025-01975-4. PMCID: PMC12210944.